Most Read Articles
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.

Hormonal contraceptive may up risk of breast cancer

Tristan Manalac
23 Dec 2017
Kratom capsules being sold in the United States. Photo credit: AP/New York Post

Contemporary hormonal contraceptives appear to increase the risk of breast cancer, particularly in those with long durations of exposure, a recent study from Denmark has shown.

However, while the current study did not take into consideration additional breast cancer cases after the discontinuation of hormonal contraception, the absolute increase in risk is low, researchers said.

In 1,797,932 females without cancer or venous thromboembolism, there were 11,517 incident cases of breast cancer over a mean follow-up of 10.9±5.8 years. The current or recent use of any hormonal contraception significantly elevated the risk of breast cancer compared with never use (relative risk [RR], 1.20; 95 percent CI, 1.14–1.26; p=0.002). [N Engl J Med 2017;377:2228-2239]

Moreover, the duration of hormonal contraception had a significant effect on the risk of breast cancer (p=0.002), such that those with <1 year of use have lower risks (RR, 1.09; 0.96–1.23) than those with >10 years of use (RR, 1.38; 1.26–1.51).

Further stratification showed that the risk of breast cancer was only elevated in females with prolonged use (≥5 years), and that the increased risk persisted for at least 5 years after discontinuation of contraception (RR, 1.30; 1.06–1.58). In contrast, <5 years of exposure had no apparent impact on breast cancer risk.

“Our results suggest the rapid disappearance of excess risk of breast cancer after discontinuation of use among women who have used hormonal contraceptives for short periods, whereas the risk among women who have used these contraceptives for longer periods may persist for at least 5 years after discontinuation,” researchers said.

The age-standardized incidence rates of breast cancer for those with and without current or recent exposure to hormonal contraception were 55 and 58 events per 100,000 person-years, resulting in an age-adjusted risk difference of 3.

Despite the statistical link between the use of hormonal contraception in the past 6 months and the elevated risk of breast cancer, researchers said that, practically, the absolute increase in breast cancer cases as a result of hormonal contraception is low.

“[A]pproximately one extra breast cancer was diagnosed for every 7,690 women using hormonal contraception for 1 year… This risk should be weighed against important benefits of hormonal contraceptives such as good contraceptive efficacy and reduced risks of ovarian, endometrial, and perhaps colorectal cancer,” they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

17 Feb 2019
In patients with type 2 diabetes (T2D), sodium-glucose cotransporter 2 (SGLT2) inhibitor monotherapy, particularly canagliflozin, exerts greater effects on weight compared with metformin and dipeptidyl peptidase 4 (DPP-4) inhibitors or gliptins, according to the results of a meta-analysis.
Roshini Claire Anthony, 20 Mar 2018

Individuals with type 2 diabetes (T2D) who initiate therapy with sodium glucose cotransporter-2 (SGLT-2) inhibitors have lower risks of all-cause death and cardiovascular (CV) outcomes, specifically myocardial infarction (MI) and stroke, compared with those who initiate other glucose-lowering therapies, according to results from the CVD-REAL* 2 study.

20 Feb 2019
A recent study has shown that compounded topical pain creams are only as effective as placebo creams in the treatment of localized chronic pain. Their costs are also higher compared with approved compounds, which should discourage routine use.